Clinical Trial Detail

NCT ID NCT01969643
Title A Safety Study of SGN-LIV1A in Breast Cancer Patients
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Seattle Genetics, Inc.
Indications

Her2-receptor negative breast cancer

triple-receptor negative breast cancer

Therapies

Ladiratuzumab vedotin

Ladiratuzumab vedotin + Trastuzumab

Age Groups: senior adult

Additional content available in CKB BOOST